Physicians' Academy for Cardiovascular Education

EAS 2019

News from the EAS 2019 congress, held in Maastricht, The Netherlands on May, 26-29.

Efforts to move universal cholesterol screening before the age of 20 forward

3' education - May 29, 2019 - Maastricht, The Netherlands - Professor Kausik Ray, MD
Prof. Kausik Ray talks about the Familial Hypercholesterolemia Studies Collaboration, which was established to address the unmet need to influence global policy change regarding screening for FH patients early in life.

EAS 2019 Prof. Kausik Ray talks about the Familial Hypercholesterolemia Studies Collaboration, which was established to address the unmet need to influence global policy change regarding screening for FH patients early in life.

Positive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein, MD
Prof. Evan Stein summarizes novel phase II data of a new 'small binding protein', consisting of adnectin and human albumin, which inhibits PCSK9. The results were such that a phase 3 trial has now started to further study the compound.

EAS 2019 Prof. Evan Stein summarizes novel phase II data of a new 'small binding protein', consisting of adnectin and human albumin, which inhibits PCSK9. The results were such that a phase 3 trial has now started to further study the compound.

More intelligent intervention through more strategic use of CV biomarkers

3' education - May 28, 2019 - Maastricht, The Netherlands
Prof. Chris Packard distinguishes various types of biomarkers. Thinking about them in this way can provide a framework for more intelligent use of biomarkers.

EAS 2019 Prof. Chris Packard distinguishes various types of biomarkers. Thinking about them in this way can provide a framework for more intelligent use of biomarkers.

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc
Prof. Chapman lists the newest findings on the associations of Lp(a) levels, PCSK9 inhibitors and CV risk, based on new analyses of the FOURIER and ODYSSEY OUTCOMES trials.

EAS 2019 Prof. Chapman lists the newest findings on the associations of Lp(a) levels, PCSK9 inhibitors and CV risk, based on new analyses of the FOURIER and ODYSSEY OUTCOMES trials.

Growing importance of lowering remnants, also in light of the obesity epidemic

EAS 2019 - Maastricht, The Netherlands

3' education - June 3, 2019 - Børge Nordestgaard
Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

EAS 2019 Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

Debate on Lp(a) – treating high levels or not?

News - May 29, 2019
By debating on whether high Lp(a) levels should be treated or not, Brian Ference and Sotirios Tsimikas critically reviewed the available evidence on the link between Lp(a) and CV risk.

EAS 2019 By debating on whether high Lp(a) levels should be treated or not, Brian Ference and Sotirios Tsimikas critically reviewed the available evidence on the link between Lp(a) and CV risk. With poll

Moving from ignorance on the complexity of HDL to novel therapeutic opportunities

EAS 2019 - Maastricht, The Netherlands

3' education - June 3, 2019 - John Chapman, DSc
Emerging evidence reveals that

EAS 2019 Emerging evidence reveals that "HDL" represents an enormously heterogeneous mixture of particles, with varying structural, compositional, metabolic and functional properties.

Clinical interest in HDL is historically low, but research into HDL never stopped. With interesting results

News - May 30, 2019
Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.

EAS 2019 Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.

Failure to identify FH results in worse survival compared with people with an FH diagnosis

News - May 31, 2019
A UK study involving over 1.7 million health records in the general population suggests that a considerable number of people may have FH but are not diagnosed yet, leading to premature mortality

EAS 2019 A UK study involving over 1.7 million health records in the general population suggests that a considerable number of people may have FH but are not diagnosed yet, leading to premature mortality

Genetic study reveals variants that are associated with lipid species and CV risk

News - May 29, 2019
A consortium of Finnish, German and US centres performed GWAS, combined with phenome-wide scans, to integrate information from the lipidome, genome and phenome.

EAS 2019 A consortium of Finnish, German and US centres performed GWAS, combined with phenome-wide scans, to integrate information from the lipidome, genome and phenome.

Effect of IL-1β inhibition on lung cancer sheds new light on the role of inflammation

EAS 2019 - Maastricht, The Netherlands

3' education - May 28, 2019 - EAS 2019, Maastricht - Paul Ridker, MD
Paul Ridker discusses the positive effect of canakinumab on non-small cell lung cancer incidence and mortality, as demonstrated in the CANTOS trial.

EAS 2019 Paul Ridker discusses the positive effect of canakinumab on, in particular, non-small cell lung cancer incidence and mortality, as demonstrated in the CANTOS trial.

Genetic variants and elevated risk of CAD

EAS 2019 - Maastricht, The Netherlands

3' education - May 28, 2019 - Heribert Schunkert, MD - Munich, Germany
Heribert Schunkert and his team identified genetic variants that increase the risk of CAD. While many only exert a small effect, they did some striking observations on large increases of CV risk.

EAS 2019 Heribert Schunkert and his team identified genetic variants that increase the risk of CAD. While many only exert a small effect, they did some striking observations on large increases of CV risk.